TScan Therapeutics, Inc.
TCRX
$1.44
$0.1410.77%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -86.62% | -44.71% | -25.65% | -14.47% | 55.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -86.62% | -44.71% | -25.65% | -14.47% | 55.52% |
| Cost of Revenue | 68.50% | -81.41% | -84.24% | -91.10% | -95.19% |
| Gross Profit | -111.17% | 91.05% | 101.04% | 117.86% | 139.26% |
| SG&A Expenses | 14.92% | 7.95% | 6.17% | 8.65% | 29.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.20% | 19.64% | 25.06% | 29.12% | 42.83% |
| Operating Income | -44.26% | -31.64% | -35.13% | -39.43% | -40.25% |
| Income Before Tax | -42.91% | -26.01% | -27.99% | -33.28% | -34.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.91% | -26.01% | -27.99% | -33.28% | -34.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.91% | -26.01% | -27.99% | -33.28% | -34.73% |
| EBIT | -44.26% | -31.64% | -35.13% | -39.43% | -40.25% |
| EBITDA | -48.37% | -34.75% | -38.42% | -43.08% | -43.25% |
| EPS Basic | -3.80% | 18.58% | 26.78% | 32.60% | 15.32% |
| Normalized Basic EPS | -2.98% | 18.58% | 26.78% | 32.60% | 15.33% |
| EPS Diluted | -3.80% | 18.58% | 26.78% | 32.60% | 15.32% |
| Normalized Diluted EPS | -2.98% | 18.58% | 26.78% | 32.60% | 15.33% |
| Average Basic Shares Outstanding | 26.15% | 40.94% | 64.31% | 97.80% | 73.71% |
| Average Diluted Shares Outstanding | 26.15% | 40.94% | 64.31% | 97.80% | 73.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |